Pharmaceutical inhibition of glycogen synthetase kinase-3β reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model
about
NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple MyelomaWnt activation followed by Notch inhibition promotes mitotic hair cell regeneration in the postnatal mouse cochlea.Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic interventionMicroRNA-214 controls skin and hair follicle development by modulating the activity of the Wnt pathway.Targeting bone as a therapy for myeloma.Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche?Targeting Wnt pathways in disease.Wnt and Wnt inhibitors in bone metastasis.Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.An unexpected role for a Wnt-inhibitor: Dickkopf-1 triggers a novel cancer survival mechanism through modulation of aldehyde-dehydrogenase-1 activity.Kinase inhibitors as potential agents in the treatment of multiple myeloma.Titanium particle-induced osteogenic inhibition and bone destruction are mediated by the GSK-3β/β-catenin signal pathway.Rapid Osteogenic Enhancement of Stem Cells in Human Bone Marrow Using a Glycogen-Synthease-Kinase-3-Beta Inhibitor Improves Osteogenic Efficacy In Vitro and In Vivo.Small molecule enhancers of rapamycin induce apoptosis in myeloma cells via GSK3A/B preferentially within a protective bone marrow microenvironment.
P2860
Q28080823-901ED922-2ED5-481F-B9FA-E631B5134523Q30360502-5E380249-9C57-4796-867D-3A381D7ACD38Q33558170-B9311445-03D0-462D-828F-6BF9CDF43A8BQ34049686-F9A84B80-99CA-4EDA-B57B-FB042B70C451Q34566695-94361B59-FE5F-4F5D-9920-41F6C89B567BQ35603128-7FC83801-3AE6-4B12-B97A-E874F30F2745Q36289608-4575F0C4-6A33-4152-A75E-DDC5545F4D2EQ36506697-A6DA6359-0A68-436F-9FCC-1F6B568B04ADQ37056355-D0EF5063-6775-425A-915E-6DA91E2EC053Q37460101-74C38349-B9D9-4D6B-993E-E35B8B0B03FEQ37620723-140BBCB6-5183-4312-98F6-857A6A4D4D5EQ37697253-1D907301-7302-4AA8-9F21-1D023EFA3EDBQ41084327-52C04F6C-3420-4D10-A31D-8983BE264F37Q48098707-A510CC3C-2198-4C0F-B6BF-F22D2CF425F6Q54345704-A4DEBC91-FDD3-4E7F-8A93-6F09F3352F32
P2860
Pharmaceutical inhibition of glycogen synthetase kinase-3β reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Pharmaceutical inhibition of g ...... e plasmacytoma xenograft model
@ast
Pharmaceutical inhibition of g ...... e plasmacytoma xenograft model
@en
type
label
Pharmaceutical inhibition of g ...... e plasmacytoma xenograft model
@ast
Pharmaceutical inhibition of g ...... e plasmacytoma xenograft model
@en
prefLabel
Pharmaceutical inhibition of g ...... e plasmacytoma xenograft model
@ast
Pharmaceutical inhibition of g ...... e plasmacytoma xenograft model
@en
P2860
P1433
P1476
Pharmaceutical inhibition of g ...... e plasmacytoma xenograft model
@en
P2093
P2860
P304
P356
10.1182/BLOOD-2010-09-308171
P407
P577
2010-12-01T00:00:00Z